<p>Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights</p>
Jason S. Starr, Mohamad Bassam Sonbol, Timothy J. Hobday, Akash Sharma, A. Tuba Kendi, Þorvarður R. Hálfdánarson
Abstract
Peptide receptor radionuclide therapy (PRRT) is a paradigm shifting approach to the treatment of neuroendocrine tumors. Although there are no prospective randomized trials directly studying PRRT in pancreatic neuroendocrine tumors (panNETs), there are data to suggest benefit in this patient population. Collectively, the data, consisting of two prospective and six retrospective studies, show a median PFS ranging from 20 to 39 months and a median OS ranging from 37 to 79 months. There are ongoing (and upcoming) prospective, randomized trials of PRRT in panNETs, which will provide further evidence to support this approach.
Topics & Concepts
Radionuclide therapyNeuroendocrine tumorsPeptide receptorMedicineOncologyInternal medicinePopulationProspective cohort studyPancreatic neuroendocrine tumorReceptorEnvironmental healthNeuroendocrine Tumor Research AdvancesLung Cancer Research StudiesNeuroblastoma Research and Treatments